China’s COVID Vaccine Effective in Kids – Study
China-made COVID-19 vaccine, CoronaVac, has found to be effective in kids aged 3-17
The development that definitely steps up the global fight against coronavirus, China-made COVID-19 vaccine, CoronaVac, has found to be effective in kids.
According to the findings of a new study published in current issue of The Lancet Infectious Diseases journal, CoronaVac has been found to be safe in paediatric use. The vaccine has shown to produce a strong antibody response among children and adolescents aged between 3-17 years, the study revealed.
The phase 1/2 trials for CoronaVac were conducted on 550 participants in Zanhuang County, China.
While 72 participants were enrolled in phase 1 trial between October 31 and December 2, 2020, another 480 participants were enrolled in phase 2 held between December 12 and December 30, 2020. The participants were administered the vaccine either 1.5 microgram per dose, 3 microgram per dose or a control placebo through intramuscular injections in two doses, at day 0 and day 28.
At the end of the trials over 96 per cent of participants who received both doses of the vaccine developed a strong antibody response against SARS-CoV-2, the virus responsible for the spread of COVID-19.
Only one adverse reaction was reported in the control group. For others “most adverse reactions were mild or moderate, with pain at the injection site the most commonly reported symptom, said Qiang Gao from Sinovac Life Sciences, China.
